Ketobemidone

Ketobemidone
Clinical data
Trade names	Ketogan
Other names	Ketobemidone, Cliradon, Cymidon, Ketogan, Ketorax
AHFS/Drugs.com	International Drug Names
Routes of; administration	By mouth, rectal, intravenous
ATC code	N02AB01 (WHO) ;
Legal status
Legal status	AU: S9 (Prohibited substance); BR: Class F1 (Prohibited narcotics); CA: Schedule I; DE: Anlage II (Authorized trade only, not prescriptible); US: Schedule I; EU: Rx-only;
Pharmacokinetic data
Bioavailability	34~40% (oral), 44% (rectal)
Elimination half-life	2–4 hours
Duration of action	3–5 hours
Identifiers
	IUPAC name 1-[4-(3-Hydroxyphenyl)-1-methyl-4-piperidyl]propan-1-one;
CAS Number	469-79-4 ;
PubChem CID	10101;
DrugBank	DB06738 ;
ChemSpider	9697 ;
UNII	PQS1L514CF;
KEGG	D08100 ;
ChEMBL	ChEMBL47072 ;
CompTox Dashboard (EPA)	DTXSID00196977 ;
ECHA InfoCard	100.006.748
Chemical and physical data
Formula	C15H21NO2
Molar mass	247.338 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(CC)C1(CCN(C)CC1)c2cc(O)ccc2;
	InChI InChI=1S/C15H21NO2/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12/h4-6,11,17H,3,7-10H2,1-2H3 ; Key:ALFGKMXHOUSVAD-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ketobemidone, sold under the brand name Ketogan (a mixture of ketobemidone and Spasmolytic A29) among others, is a powerful synthetic opioid painkiller. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties imparted, in part, by its metabolite norketobemidone.^[2] This may make it useful for some types of pain that do not respond well to other opioids.^[2] It is marketed in Denmark, Iceland, Norway. Until 2024 it was available in, but is now withdrawn in Sweden. It is used for severe pain.^[3]

^ https://www.ema.europa.eu/documents/psusa/ketobemidone-list-nationally-authorised-medicinal-products-psusa/0001807/202005_en.pdf ^{[bare URL PDF]}
^ ^a ^b Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H (September 1998). "Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists". Biochemical Pharmacology. 56 (5): 553–9. doi:10.1016/S0006-2952(98)00088-4. PMID 9783723.
^ Brayfield A, ed. (9 January 2017). "Ketobemidone Hydrochloride: Martindale: The Complete Drug Reference". MedicinesComplete. London, UK: Pharmaceutical Press. Retrieved 6 September 2017.

[1] ttps://www.ema.europa.eu/documents/psusa/ketobemidone-list-nationally-authorised-medicinal-products-psusa/0001807/202005_en.pdf ^{[bare URL PDF]}

[NMDA98-2] Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H (September 1998). "Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists". Biochemical Pharmacology. 56 (5): 553–9. doi:10.1016/S0006-2952(98)00088-4. PMID 9783723.

[3] Brayfield A, ed. (9 January 2017). "Ketobemidone Hydrochloride: Martindale: The Complete Drug Reference". MedicinesComplete. London, UK: Pharmaceutical Press. Retrieved 6 September 2017.

[1]

[2]

[3]

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

Ketobemidone

Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.